High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about whether the rally has room left to run.
Aug 5 (Reuters) - There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a potential deal, a senior source close to the matter told Reuters on Wednesday, quashing the prospect of a mooted mega merger between the drugmakers. "There is no deal between AstraZeneca and BMS.
A source close to the matter told Reuters there is "no deal" and there "never was a deal to be done" between the two drugmakers
Chief Executive Mike Doustdar’s comments come amid sector focus on M&A and after Novo Nordisk made two disclosures in recent days on its future pipeline that disappointed investors.
AstraZeneca (NASDAQ: AZN) and Bristol Myers Squibb (NYSE: BMY) are the two directly affected public companies; AZN bears the most immediate price risk given it absorbed a roughly 9% single-day selloff on Monday when the merger speculation first emerged, while BMY shareholders were widely viewed as the primary beneficiaries of any combination.
AMD is on the verge of a sales jump, pharma investors await M&A boom, a new food contaminant issue, and more news to start your day.
Two of the world's biggest drugmakers moved in opposite directions on Monday, and the split says a lot about how Wall Street reads a merger. Reports surfaced over the weekend that AstraZeneca (AZN) had held talks about combining with Bristol Myers Squibb (BMY). The deal would be worth close ...
The merger talks between the two companies remain active, Semafor reported.
Pfizer beats Q2 earnings and revenue estimates, raises the low end of its 2026 sales outlook, but lowers expectations for COVID product revenues.
BMY vs. AMGN: Which Stock Is the Better Value Option?
Bristol Myers Squibb's (BMY) reported merger discussions with AstraZeneca (AZN) will unlikely result
Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) share price after Monday's sharp fall, while Deutsche Bank sees clear parallels with the drugmaker's Alexion acquisition five years ago. The two notes are the second-day response to a...
BioNTech (NASDAQ:BNTX) reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year quarter also benefited from a one-time compensation payment from Pfizer related to its decision to opt
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here is how Perspective Therapeutics (CATX) and Bristol Myers Squibb (BMY) have performed compared to their sector so far this year.
Bristol Myers (BMY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
AstraZeneca (LSE:AZN) is reported to be in advanced merger talks with Bristol Myers Squibb. The potential deal could create a combined pharmaceutical company valued at about US$400b. The transaction, if completed, would rank among the largest in the sector and could significantly affect competitive positions in oncology. Regulators are expected to review any agreement closely due to overlapping product portfolios. AstraZeneca is a global pharmaceutical company with a significant focus on...
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Big drug companies have been buying scrappy biotechs to expand their pipelines, but the potential megamerger between AstraZeneca and Bristol Myers Squibb could flip that script.
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
Amazon crossed a $3 trillion market value, Snowflake rose as investors showed more confidence in its AI business, and Bristol-Myers stock climbed on possible merger discussions.
Growth portfolio now drives 60% of revenue as Eliquis surges 21%.
Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to a gene therapy for a rare metabolic disorder, putting biotech investors on high alert.
Bristol-Myers stock extends gains on reports of a potential merger with AstraZeneca. But caution is warranted in chasing the momentum in BMY shares today.
Investors questioned whether combining AstraZeneca with Bristol Myers would strengthen growth enough to justify the financial and regulatory risks.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
